IDEAYA Biosciences, Inc. $IDYA Shares Sold by Candriam S.C.A.

Key Points

• Candriam S.C.A. has decreased its stake in IDEAYA Biosciences by 12.5%, now holding approximately 938,177 shares worth about $15.37 million.
• Shares of IDEAYA opened at $24.32, with a one-year trading range between $13.45 and $40.74.
• Analysts have given IDEAYA an average rating of "Moderate Buy", with price targets ranging from $25.00 to $72.00.

Candriam S.C.A. cut its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 12.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 938,177 shares of the company's stock after selling 133,648 shares during the quarter. Candriam S.C.A. owned 1.07% of IDEAYA Biosciences worth $15,367,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. CWM LLC lifted its holdings in IDEAYA Biosciences by 325.7% during the 1st quarter. CWM LLC now owns 2,371 shares of the company's stock worth $39,000 after buying an additional 1,814 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of IDEAYA Biosciences by 180.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock valued at $39,000 after purchasing an additional 1,546 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of IDEAYA Biosciences in the 4th quarter valued at approximately $47,000. Signaturefd LLC increased its position in shares of IDEAYA Biosciences by 374.8% in the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company's stock valued at $47,000 after purchasing an additional 2,271 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its position in shares of IDEAYA Biosciences by 46.4% in the 1st quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock valued at $109,000 after purchasing an additional 2,112 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Trading Down 1.9%

Shares of NASDAQ IDYA traded down $0.4830 during mid-day trading on Monday, reaching $24.6370. The company had a trading volume of 471,744 shares, compared to its average volume of 1,136,689. The firm has a 50 day simple moving average of $22.98 and a two-hundred day simple moving average of $20.36. The stock has a market cap of $2.16 billion, a P/E ratio of -6.50 and a beta of 0.09. IDEAYA Biosciences, Inc. has a 52-week low of $13.45 and a 52-week high of $40.74.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.03). The company had revenue of $6.00 million for the quarter, compared to analysts' expectations of $3.48 million. IDEAYA Biosciences's revenue was up NaN% on a year-over-year basis. During the same quarter last year, the business earned ($0.68) earnings per share. On average, equities analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on IDYA shares. TD Cowen started coverage on shares of IDEAYA Biosciences in a research report on Tuesday, July 22nd. They issued a "buy" rating on the stock. JPMorgan Chase & Co. increased their price objective on shares of IDEAYA Biosciences from $66.00 to $72.00 and gave the company an "overweight" rating in a research report on Monday, July 28th. Wells Fargo & Company started coverage on shares of IDEAYA Biosciences in a research report on Thursday, June 26th. They issued an "overweight" rating and a $44.00 price objective on the stock. The Goldman Sachs Group raised shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 price objective on the stock in a research report on Thursday, July 10th. Finally, Royal Bank Of Canada raised shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and dropped their price objective for the company from $57.00 to $30.00 in a research report on Wednesday, July 9th. Ten analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, IDEAYA Biosciences currently has a consensus rating of "Moderate Buy" and an average price target of $48.09.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.